Novartis (NVS) Stock Price

$112.6 0%

Sign up
to add to portfolio

AI Score

Hold

  • Alternative

    5

  • Fundamental

    8

  • Technical

    6

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Novartis, AI stock picks, stock alerts and much more.

Sign up

NVS AI Stock Analysis

AI stock analysis for NVS is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Novartis (NVS) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Novartis (NVS) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Novartis (NVS), currently trading at $112.6, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About NVS

LSE

  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide.

  • Symbol

    NVS

  • Market

    NYSE

  • Industry

    Drug Manufacturers - General

  • Market Cap

    222.4B

Similar Stocks

JNJ Johnson & Johnson
JNJ		 $153.6
0.8%
5
LLY Eli Lilly and Company
LLY		 $722.6
0.4%
7
PFE Pfizer
PFE		 $23.45
1.2%
4
ABBV AbbVie
ABBV		 $185.6
1.4%
6
MRK Merck & Company
MRK		 $76.4
0.3%
5

News

Novartis announces commencement of tender offer to acquire Regulus Therapeutics

Novartis announces commencement of tender offer to acquire Regulus Therapeutics
May 27, 2025. globenewswire.com
Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?

Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?
May 15, 2025. zacks.com
Should Value Investors Buy Novartis (NVS) Stock?

Should Value Investors Buy Novartis (NVS) Stock?
May 15, 2025. zacks.com
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
May 15, 2025. globenewswire.com

NVS Alternative Data

Web Traffic

Novartis receives an estimated 1.1M monthly visitors to novartis.com.

  • Web Traffic

    1119832

  • Change from Previous Month

    2.3%

  • 3 Month Change

    8.4%

  • YoY Change

    8.4%

Twitter Followers

Novartis has 292,631 Twitter Followers on its main Twitter (also known as X) account, which is down by -0.5% over the last month.

  • Twitter Followers

    292631

  • Daily Change

    0%

  • 1 Month Change

    0.5%

  • 3 Month Change

    0.9%

  • YoY Change

    0.9%

Facebook Engagement

Novartis has engaged 312 users via their Facebook Page over the last 7 days.

  • Facebook Engagement

    312

  • Daily Change

    6.6%

  • 1 Month Change

    271.4%

  • 3 Month Change

    52.2%

  • YoY Change

    52.2%

Instagram Followers

Novartis has 123,154 Instagram Followers on its main Instagram account, up by 0.4% over the last month.

  • Instagram Followers

    123154

  • Daily Change

    0%

  • 1 Month Change

    0.4%

  • 3 Month Change

    0.8%

  • YoY Change

    0.8%

Youtube Subscribers

Novartis has 46,200 subscribers on its main Youtube channel, up by 2% over the last month.

  • Youtube Subscribers

    46200

  • Daily Change

    0%

  • 1 Month Change

    2%

  • 3 Month Change

    17%

  • YoY Change

    17%

LinkedIn Followers

4,153,426 are following Novartis on LinkedIn, up by 0.7% over the last month.

  • LinkedIn Followers

    4153426

  • Daily Change

    0%

  • 1 Month Change

    0.7%

  • 3 Month Change

    1.9%

Job Postings

Novartis currenly has an estimated 2,000 open job postings.

  • Job Postings

    2000

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    100%

  • YoY Change

    100%

LinkedIn Employees

According to LinkedIn, Novartis has 78,933 employees, down by -0.2% over the last month.

  • LinkedIn Employees

    78933

  • Daily Change

    0%

  • 1 Month Change

    0.2%

  • 3 Month Change

    0%

  • YoY Change

    0%

Reddit Mentions

Novartis has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    100%

  • 3 Month Change

    100%

Business Outlook

According to employee reviews, the business outlook among employees at Novartis is 73 out of 100 (bullish).

  • Business Outlook

    73

  • Change from Previous Month

    0%

  • 3 Month Change

    1.4%

  • YoY Change

    1.4%

News Mentions

Novartis was mentioned 10 times in the news yesterday.

  • News Mentions

    10

  • Daily Change

    41.2%

  • 1 Month Change

    0%

  • 3 Month Change

    100%

NVS Financials

NVS Key Metrics

  • Total Revenue

    $13.6B

  • Net Income

    $3.6B

  • Earnings per Share

    $1.83

  • Free cash flow

    $2.2B

  • EBITDA

    $5.8B

  • EBITDA Ratio

    0.42812

  • Total Assets

    $99.9B

NVS 2-year Revenue & Income
NVS 2-year Free Cash Flow

NVS Technicals

NVS SMA
NVS RSI

FAQ

What's the current price of Novartis (NVS) Stock?
The price of an Novartis (NVS) share is $112.6.

What's the market cap of Novartis?
The current market cap of Novartis is 222.4B.

Should I buy or sell NVS?
Novartis shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Novartis is better viewed as a hold or accumulate position while waiting for further developments.

Is Novartis a good investment?
The current analysis of Novartis' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Novartis' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.

Is now a good time to buy Novartis (NVS) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Novartis stock is currently neutral, suggesting a cautious approach might be wise.

What are some stocks similar to Novartis (NVS) that investors often compare it to?
Novartis (NVS) is often compared to similar stocks such as Johnson & Johnson, Eli Lilly and Company, Pfizer, AbbVie and Merck & Company.

What is the forecast for Novartis' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Novartis' stock price to be around $115.7 in 2026. Starting from the current price of $112.6, this represents a 2.8% change in price, indicating a neutral outlook for the stock.

How to buy Novartis (NVS) Stock?
Novartis stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Novartis shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.